Related Experiment Video
Updated: Aug 12, 2026

Tumor Transplantation for Assessing the Dynamics of Tumor-Infiltrating CD8+ T Cells in Mice
Published on: June 12, 2021
[Tumor cell immunogenicity and T-cell-mediated antitumor immune reactions. Modulation and application to
Several approaches to increase tumor cell immunogenicity and anti-tumor T-cell reactivity have been reviewed. In contrast to unspecific immune stimulation, the activation of specific T-cell reactivity can lead to long-lasting anti-tumor immunity. In several instances, immunization with modified tumor cells led to the induction of tumor immunity against the original non-modified tumor cells. In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen. Postoperative immunization with either virus modified ESb cells or with mutagenized variants of ESb cells led to the survival of a significant proportion of the treated animals. These animals had been cured of their micrometastases and developed long lasting anti-tumor immunity. It is hoped that such modified tumor cells could become useful reagents for tumor immunotherapy, especially in situations where the tumor burden is low. Future efforts should be directed towards testing the effectiveness of immunogenic modified tumor variants in combination with surgery or chemotherapy for treatment of micrometatases.
Several approaches to increase tumor cell immunogenicity and anti-tumor T-cell reactivity have been reviewed. In contrast to unspecific immune stimulation, the activation of specific T-cell reactivity can lead to long-lasting anti-tumor immunity. In several instances, immunization with modified tumor cells led to the induction of tumor immunity against the original non-modified tumor cells. In our own studies two types of approaches were also effective with the highly metastatic mouse tumor line ESb which carries a weak tumor associated antigen. Postoperative immunization with either virus modified ESb cells or with mutagenized variants of ESb cells led to the survival of a significant proportion of the treated animals. These animals had been cured of their micrometastases and developed long lasting anti-tumor immunity. It is hoped that such modified tumor cells could become useful reagents for tumor immunotherapy, especially in situations where the tumor burden is low. Future efforts should be directed towards testing the effectiveness of immunogenic modified tumor variants in combination with surgery or chemotherapy for treatment of micrometatases.
Related Concept Videos
Cell-mediated Immune Responses
The Tumor Microenvironment
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...
Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

